p73, a new p53 family member, is a transcription factor that is increasingly recognized in cancer research as an important player in tumorigenesis as well as in chemotherapeutic drug sensitivity. Despite the substantial structural and functional similarities to p53, accumulating evidence suggests that p53 and p73 may differently regulate their transcriptional targets. In this study, we have investigated the role of p73 in regulation of the gastrin gene promoter. Gastrin is a peptide hormone and an important factor in determining the progression of a number of human malignancies. Our results show that p73 can bind to the gastrin promoter. This leads to transcriptional upregulation of gastrin mRNA. We also found that the levels of gastrin and p73 transcripts correlate in primary gastric tumors. Taken together, our results demonstrate a novel mechanism for regulation of gastrin gene transcription and support a concept that p53 and p73 may have different biological roles in tumors.
p73 is a transcription factor and a homolog of p53 tumor suppressor. p73 shares substantial structural and functional similarity with p53. When overexpressed, p73 can mimic almost all of p53's biological activities. This includes transactivation of an overlapping set of target genes, induction of apoptosis and cell cycle arrest. In reporter assays, p73 can activate transcription from most of the p53 target genes that are involved in cell cycle regulation and apoptosis (for a review see Moll et al., 2001) . However, despite these similarities there are a number of important differences. p73 expresses as a complex variety of protein isoforms that originate from two p73 gene promoters and extensive gene splicing at the NH2-and COOH-termini. In addition, p73 gene encodes a domain at the COOH-terminus that is not found in p53. This domain, termed SAM or sterile alpha motif, is responsible for protein-protein interactions and is found in a diverse range of proteins that are involved in developmental regulation. Splicing at the COOH-terminus can produce p73 isoforms with and without SAM domain. For example, the most abundant p73a isoform carries the SAM domain; p73b does not. However, the most important dissimilarity is that p73 and p53 behave differently in the context of human tumors. In fact, in striking difference to p53, which is frequently mutated, data from over 1400 primary tumors, including solid and hematological ones, demonstrated that loss-of-function mutations of p73 are rare (Benard et al., 2003) . Surprisingly, at the same time p73 isoforms are specifically overexpressed in tumor tissues compared with their normal counterparts (Tokuchi et al., 1999; Zaika et al., 1999; Ng et al., 2000; Weber et al., 2002; Guan et al., 2003; Tomkova et al., 2004) . Moreover, in a number of tumors p73 overexpression correlates with poor patient survival (Tannapfel et al., 1999; Liu et al., 2001; Sun, 2002) . Taken altogether, these data suggest that at the molecular level p73 may be involved in signaling pathways distinct from p53. Considering the significant role of the p53 protein family, elucidation of these pathways is an important prerogative in cancer research.
Gastrin is a secreted peptide hormone, which has been discovered as a regulator of gastric acid secretion in the stomach. Normally, it is also produced in the upper small intestine, colon and pancreas. The gastrin biosynthesis starts from a large precursor molecule, preprogastrin, which is processed further to yield several intermediates and mature hormone. Incompletely processed gastrins (progastrin and glycine-extended gastrin (Gly-gastrin)) are biologically active and have growthpromoting effects on gastrointestinal cells in vitro and in vivo Brown et al., 2003; Singh et al., 2003; Aly et al., 2004) . Overexpression of both progastrin and Gly-gastrin in transgenic animals induces increased colonic proliferation and accelerates the development of colon cancer (Wang et al., 1996; Koh et al., 1999; Aly et al., 2001; Cobb et al., 2004) . It also emerges that gastrins are also involved in human tumorigenesis. They are upregulated in numerous cancers including colorectal, pancreatic, ovarian and lung cancers (Kochman et al., 1992; Ciccotosto et al., 1995; Caplin et al., 2000; Goetze et al., 2000) . Moreover, in lung cancer the upregulation of Gly-gastrin correlates with a significantly worse mean survival in patients (Koh et al., 2004) . Notably, despite the important role of gastrins in tumorigenesis, the regulation of the gastrin gene expression is not well understood.
In this study, we show that p73 can bind and activate human and murine gastrin promoter. This leads to upregulation of gastrin transcript level. Moreover, p73 transcript level correlates with gastrin expression in gastric tumors.
Previously, we and others have found that p73 transcription factor is highly overexpressed in human gastric tumor tissues compared to normal mucosa levels (Kang et al., 2000; Tannapfel et al., 2001; Tomkova et al., 2004) . In striking contrast to p53, which is frequently mutated, it has been demonstrated that lossof-function mutations of p73 are rare. In gastric and esophageal carcinomas, only one mutation was observed in a series of 92 tumors (Nimura et al., 1998; Han et al., 1999; Pilozzi et al., 2003) . Moreover, recent studies of large patient groups with hepatocellular carcinomas, colorectal carcinomas, and breast cancer have found a statistically significant correlation between high global expression of the p73 protein and poor clinical outcome (Benard et al., 2003) . Thus, considering these differences it is plausible to propose that p73 has a subset of transcriptional targets that are different from p53.
We explored a possibility that gastrin gene is a transcriptional target for p73 in cancer cells. To assess the effect of p73 on gastrin gene transcription, we employed two luciferase reporter constructs, which contain 1.3 kb human and 1 kb murine gastrin promoter fragments, respectively. AGS gastric cancer cells were co-transfected with p73a or p73b plasmids along with these reporters. Our results demonstrated considerable induction of human and murine gastrin promoters by both isoforms of p73 (Figure 1a and b). Similar upregulation was observed in lung cancer cell line H1299 (data not shown). It is well accepted that p73 is a p53-like transcription factor that upregulates a majority of p53 transcriptional targets. Surprisingly, in contrast to the observed induction of gastrin by p73 isoforms, transfection of p53 resulted in the suppression of the human and murine gastrin gene reporters ( Figure  1a and b). Therefore, despite the fact that p73 is a p53-like transcription factor, p73 has different effects on gastrin reporters. To be certain that the different ranges of gastrin gene induction do not result from different expression levels of p53 homologs, we measured their protein expression levels using Flag-tagged p53 and p73 constructs. Our Western Blot analysis with anti-flag antibody shows that p53 and p73 isoforms are expressed at comparable levels ( Figure 1c ). Thus, difference in induction of gastrin promoter by p53 homologs is indeed the matter of intrinsic properties of these proteins but not the expression deviations.
In order to validate our findings, we examined the effect of p73 on gastrin gene transcription. We accessed the endogenous level of gastrin mRNA followed by p73 transient transfection of H1299 and AGS cells. Quantitative real-time Polymerase chain reaction (PCR) demonstrated that p73 can substantially increase gastrin mRNA level with the greatest increase observed with transfection of p73b when compared to the empty vector transfection (Figure 2a) . We found a similar upregulation in AGS cells (data not shown). Co-transfection of DNp73a, a dominant-negative transcriptional inhibitor of p73 (Zaika et al., 2002) , suppressed the effect of p73a and p73b isoforms suggesting that indeed the Ham media (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum. AGS cells were seeded into 24-well plates 24 h prior to transfection. Then, cells were co-transfected with 600 ng corresponding expression plasmid or empty vector, 100 ng luciferase reporter plasmid and 10 ng pRL-TK plasmid using FuGENE 6 reagent (Roche, Indianapolis, IN, USA). Luciferase activity was determined 18 h after transfection using Dual-Luciferase Reporter Assay kit (Promega, Madison, WI, USA). Results were normalized for Renilla luciferase activity. Results are the average7s.d. of three independent experiments. (c) Protein expression analysis of Flag-tagged p53, p73a and p73b in luciferase reporter samples using Western blotting with anti-Flag M2 antibody (Sigma, St Louis, MO, USA). Analogous to the luciferase reporter assay above, gel loading was normalized for Renilla luciferase activity.
Gastrin gene regulation K Tomkova et al transcriptional activity of p73 plays a role in this upregulation. As an additional positive control, we employed transfection with b-catenin mutant that has previously been reported to be able to upregulate gastrin gene . We found that an increase of gastrin gene transcription by p73 isoforms is comparable with b-catenin. Moreover, p73b was considerably more active than a b-catenin mutant (Figure 2a) .
To demonstrate that not only overexpressed p73 protein plays a role in the regulation of gastrin level but also its endogenous counterpart, we employed the short interfering RNA (siRNA) approach. Indeed, Figure 2b shows that downregulation of the endogenous p73 protein by siRNA leads to a decrease in gastrin transcript levels in these cells supporting our concept that p73 can regulate gastrin gene transcription. Notably, however, siRNA effect on gastrin transcript level was partial (compare control and siRNA vector transfections) most likely because other unrelated to p73 transcriptional mechanisms are involved in regulation of gastrin gene expression.
To expand our studies further, we have analyzed eight randomly selected tumor specimens from patients with gastric adenocarcinoma using a real-time reverse transcription-polymerase chain reaction (RT-PCR) with sequence-specific primers, which specifically amplify p73 and transcripts encoding gastrin (Figure 2c ). Our analysis demonstrated the correlative expression of these two genes in these tumors. Indeed, applicable nonparametric Spearman analysis shows statistically significant correlation (r ¼ 0.9, P-value ¼ 0.002) between p73 and gastrin expression. Thus, the transcript levels of p73 and gastrin correlates strongly in these tumors.
It is plausible to suggest that the activation of gastrin promoter triggered by p73 transfection might be an indirect effect mediated by a transcription factor distinct from p73. To examine this possibility, we assayed the binding of p73 to the gastrin promoter using chromatin immunoprecipitation (ChIP) that allows accessing the direct binding of p73. The ChIP analysis revealed strong p73 binding to the gastrin promoter in AGS cells After 24 h, total RNA was extracted by using the RNeasy Kit (Qiagen, Valencia, CA, USA). For cDNA synthesis, we employed the Advantage RT-for-PCR Kit (Clontech, Palo Alto, CA, USA) with 1 mg of total mRNA. The b-catenin transfection is a positive control for the experiment as has been described in Koh et al. (2000) . (b) Downregulation of p73 by siRNA leads to a decrease in gastrin transcript level. siRNA experiment was conducted as described previously (Irwin et al., 2003) . The bottom panel shows the Western Blot analysis of p73 protein using p73a (ER-15) specific antibody (Oncogene Research products, San Diego, CA, USA). Protein loading was normalized by blotting with anti-bactin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). (c) Real-time PCR analysis of p73 and gastrin gene expression in gastric tumor specimens. Levels of gastrin and p73 transcripts were analyzed with gastrin transcript-specific (5 0 -AGGGCC-CAGCCTCTCATC-3 0 , 5 0 -TCCATCCATCCATAGGCTTC-3 0 ) or p73-spesific (Tomkova et al., 2004) primers. Results were normalized to HPRT1 expression. (Figure 3a, lane 5) . Moreover, unspecific antibody (lane 2) or primers amplifying the region located distally to the gastrin promoter (lane 4) were unable to show p73 binding suggesting that the binding is indeed specific (see also Figure 3c for primer positions). Interestingly, we did not observe a direct binding of p53 protein (lane 3). However, when we tested p53 and p73 binding to the p21/Waf1 promoter, a well-characterized transcriptional target of p53, both transcription factors bound to this promoter (Figure 3b, lanes 1 and 2) . Moreover, the p53 interaction appears to be substantially stronger than p73. Thus, p73 and p53 interactions may vary in a context of different promoters.
Gastrin is a gastrointestinal hormone and growth factor that has recently been shown to activate several pathways linked to antiapoptotic effects, proliferation and cell adhesion (Hansen et al., 1976; Seva et al., 1996; Daulhac et al., 1999) . Recently, interest in incompletely processed gastrins, progastrin and Gly-extended gastrin, has dramatically increased as evidence starts to mount that these peptides are involved in gastrointestinal and lung cancer tumorigenesis (Finley et al., 1993; Seva et al., 1994; Aly et al., 2001; Koh et al., 2004) . The progastrin-expressing mice display mucosal hyperplasia and predispose mice to colon carcinomas in response to a chemical carcinogen, azoxymethane AOM, compared to wild-type control mice (Singh et al., 2000) . Targeted expression of gastrins in b-pancreatic cells in mice leads to gastric atrophy and achlorhydria, and gradual progression to dysplasia and finally gastric adenocarcinoma (Wang et al., 1996) . These tumorigenic events are exacerbated in animals infected with Helicobacter felis or H. pylori Fox et al., 2003) . Several studies have shown increased plasma progastrin levels in patients with gastric, colorectal, and pancreatic carcinomas. Although underlying molecular mechanisms of gastrins activity remain to be defined.
p53 acts as 'a guardian of genome,' protecting higher multicellular organisms against aberrant cell growth and tumor development. A similarity was found between the domains of p73 and p53 proteins. However, growing evidence is starting to mount that p73 has a set of transcriptional targets distinct from p53. In agreement with this concept, our analysis shows different regulation of gastrin gene by p73 and p53. A potential consequence of these differences might be what we observe in primary human tumors. Indeed, in contrast to p53, p73 isoforms are overexpressed specifically in tumor tissues compared with their normal counterparts, and this occurs in the absence of mutations in the p73 gene. Interestingly, considering a complexity of p73 isoforms expression, transcriptionally active isoforms of p73 are prevalent mRNA species in several analysed tumors. For instance, comprehensive analysis of p73 isoforms in hepatocellular carcinomas demonstrated that transcriptionally active p73 mRNAs are the most abundant among all the transcripts for p73 isoforms (Stiewe et al., 2004) . We have observed a similar trend in gastric and esophageal adenocarcinomas (Tomkova et al., 2004) .
In summary, we found that p73 can bind to the gastrin gene promoter and upregulate gene transcription. This novel finding may shed light on transcriptional targets of p73 in human tumors, and may suggest an explanation for the phenomenon of overexpression of p73. In these experiments, chromatin was immunoprecipitated using p73 (H-79) rabbit antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p53 (DO-7) antibody (EMD Biosciences, La Jolla, CA) or unspecific rabbit g-globulin (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). DNA released from the precipitated complexes was amplified by PCR with the human gastrin promoter-specific primers (5 0 -AGAAGAAGGCACAAGGGTG TTC-3 0 and 5 0 -CTGGACTCTGCAAACATAACGTG-3 0 ) or p21/ Waf1 promoter-specific primers (5 0 -ACCTTTCACCATTCCCC TAC-3 0 and 5 0 -GCCCAAGGACAAAATAGCCA-3 0 ). The PCR products were separated by agarose gel electrophoresis and visualized by ultraviolet illumination.
